You may not be far off-base with that thought rega

You may not be far off-base with that thought regardless of the deal context. However, one school of thought is that for the combo indication, the drug will dang near sell itself due to lack of options for patients, overcoming some potential shortfalls of a partner. As I recall, the agreement also has a number of decent provisions for CYDY to pull the rip cord if Vyera isn't performing. I'd personally ascribe about 70% of the deal terms to the TaiMed comp, and 30% to the partner not being able to drive a harder bargain.

I'm also less and less convinced that the strength of the current deal matters much at all in the long run. Continued success with cancer would most likely lead to a deal with a BP. I forget who recently asked the question about how the current deal may affect a larger deal - it may have been you asking - but my thought is that Vyera is likely to be essentially bought out of the current deal if a BP comes in after all of the big indications. Probably easier and quicker than trying to disentangle sales. Just my two cents.